The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2018Causes, Mechanism and Consequences of an Energy Crisis in Striatal Nerve Endings
Study Rationale:
Two proteins, PINK1 and parkin, prevent cell death by breaking down damaged mitochondria, cell's energy generators. Mutations in the PINK1/PRKN genes - genetic changes that render... -
Target Advancement Program, 2018Neuroprotective Effects of NFE2L1 in Parkinson's Models
Study Rationale:
NFE2L1 is a protein that controls the expression of genes involved in the differentiation and survival of dopamine neurons. NFE2L1 levels are reduced in dopamine neurons in the brains... -
Therapeutic Pipeline Program, 2018Development of ALK4290 as a Novel Parkinson's Therapeutic
Study Rationale:
There is clear evidence that the immune system plays an important role in the development and progression of Parkinson's disease. Novel therapies targeting the recruitment of immune... -
Target Advancement Program, 2018Searching for Cellular Changes Associated with PINK1 and PRKN Mutations
Study Rationale:
PINK1 and parkin are two proteins that work together to keep cells healthy by ridding them of damaged mitochondria, cells' powerhouses. Mutations (changes) in the PINK1 and PRKN genes... -
Target Advancement Program, 2018Validating Astrocyte-produced Protein GDF15 as a Novel Neuroprotective Therapy
Study Rationale:
In Parkinson's disease (PD), death of dopamine-producing brain cells takes place mainly the substantia nigra pars compacta (SN) but not in the neighboring ventral tegmental area (VTA)... -
Target Advancement Program, 2018Testing the Ability of Clenbuterol to Prevent or Modify the Course of Parkinson's Disease
Study Rationale:
Protein alpha-synuclein clumps in the brains of people with Parkinson's disease (PD), forming Lewy bodies. Recent studies have suggested that beta-2 adrenoreceptor agonists -- drugs...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.